Impact of the Reimbursement of Fibrinogen in Cardiac Surgery
ConditionCardiac Surgery
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorErasme University Hospital
About this trial
This retrospective, single-center observational study aims to evaluate the impact of fibrinogen concentrate reimbursement introduced in Belgium in April 1st, 2020, on transfusion practices in complex cardiac surgery. Adult patients undergoing complex cardiac surgery with cardiopulmonary bypass between Jan 1st 2016 and Dec 31st 2024 at Erasme Hospital will be included. Transfusion strategies and clinical outcomes will be compared between the pre-reimbursement and post-reimbursement periods.
Eligibility criteria
Qualifiers
Patients aged ≥ 18 years
Coronary artery bypass grafting combined with valve replacement
Replacement of two or more valves
Cardiac reoperation
Disqualifiers
Surgery without cardiopulmonary bypass (CPB)
Patients aged < 18 years
Pregnancy
Patients requiring postoperative extracorporeal membrane oxygenation (ECMO)
Trial design
Treatments tested in this trial
- Not listed
Trial groups
450 Participants
are grouped into 2 trial groupsSponsors and collaborators
Source ClinicalTrials.gov